Ameliora Wealth Management’s Arcturus Therapeutics ARCT Stock Holding History

Ameliora Wealth Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-150	Closed	-$1.95K	–	225
2025 Q2	$1.95K	Hold	150	–	–	﹤0.01%	207
2025 Q1	$1.59K	Hold	150	–	–	﹤0.01%	231
2024 Q4	$2.55K	Hold	150	–	–	﹤0.01%	229
2024 Q3	$3.48K	Hold	150	–	–	﹤0.01%	152
2024 Q2	$3.65K	Hold	150	–	–	﹤0.01%	172
2024 Q1	$5.07K	Hold	150	–	–	﹤0.01%	185
2023 Q4	$4.73K	Hold	150	–	–	﹤0.01%	175
2023 Q3	$3.83K	Hold	150	–	–	﹤0.01%	206
2023 Q2	$4.3K	Hold	150	–	–	﹤0.01%	183
2023 Q1	$3.6K	Hold	150	–	–	﹤0.01%	200
2022 Q4	$2.54K	Hold	150	–	–	﹤0.01%	216
2022 Q3	$2K	Buy	+150	New	+$2.52K	﹤0.01%	216

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Ameliora Wealth Management's ARCT Position: Q3 2025 in Review

Ameliora Wealth Management sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 150 shares — an estimated $1.95K sold.

Ameliora Wealth Management first reported a position in ARCT in Q3 2022 and held it in 12 quarters. The position peaked at $5.07K in Q1 2024. 137 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

Ameliora Wealth Management reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
Ameliora Wealth Management sold 150 Arcturus Therapeutics shares in Q3 2025, an estimated $1.95K.
Ameliora Wealth Management first reported a position in Arcturus Therapeutics in Q3 2022 and held it in 12 quarters.
Ameliora Wealth Management's Arcturus Therapeutics position peaked at $5.07K in Q1 2024.
137 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Ameliora Wealth Management's 13F filing for Q3 2025, filed 12 Nov 2025.